Kidney Calculi, Kidney Injury, Renal Disease, Renal Injury, Renal Stone, Ureteral Calculi, Ureteral Injury, Ureteral Obstruction, Urolithiasis, Urolithiasis, Calcium Oxalate, Urolithiasis; Lower Urinary Tract
Conditions
Keywords
Urolithiasis, Kidney Stone, Agropyron Repens, Ureteral calculi, Calcium oxalate
Brief summary
Given the high recurrence of urolithiasis in patients, the search for less aggressive and preventive treatments is increasingly necessary. Renalof® is presented as an alternative to herbal medicine being a product that, due to its diuretic and demineralization properties of kidney stones, has been widely used in this patient population, disintegrating and eliminating calcium oxalate and struvite stones in a painless in the genitourinary system. With the objective of determining the efficacy of this therapy, an observational, prospective, randomized, single-blind, two-arm study was carried out: treatment group with Renalof® and control group, placebo.
Detailed description
Given the high recurrence of urolithiasis in patients, the search for less aggressive and preventive treatments is increasingly necessary. Renalof® is presented as an alternative to herbal medicine being a product that, due to its diuretic and demineralization properties of kidney stones, has been widely used in this patient population, disintegrating and eliminating calcium oxalate and struvite stones in a painless in the genitourinary system. With the objective of determining the efficacy of this therapy, an observational, prospective, randomized, single-blind, two-arm study was carried out: treatment group with Renalof® and control group, placebo. The treatment group consists of 120 patients over 18 years of age, of both sexes, with a diagnosis of urolithiasis less than 10 mm in diameter, present throughout the entire reno-uretero-bladder path, diagnosed by ultrasound, renal CT and urography . The Renalof® product was administered at a dose of 650 mg daily for 3 months and the presence of stones in any location of the reno-ureteral tract was evaluated using one of the diagnostic means mentioned in monthly consultations. The second group, treated with placebo corresponding to 35 people constituting 30% of the universe. The study period was from August 2019 to July 2020 at the Hospital Escuela Antonio Lenin Fonseca and the Seniors clinic, in the city of Managua, Nicaragua.
Interventions
DIETARY_SUPPLEMENTRenalof
A total of 120 patients treated with the study product Renalof® at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
OTHERPlacebo
A total of 35 patients treated with Placebo at a dose of 650 mg twice daily were followed for 4 months. A preliminary analysis of the types of stones present in the study patients was performed according to the main compound, using a biophysical profile by biochemical analysis and the clinical characteristics, medical history and biochemical profile of the creatinine values of the test patients. Imaging and quality of life tests were carried out during the trial to check the efficacy and possible adverse effects of the test product in patients with kidney stones.
Sponsors
Catalysis SL
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient over 18 years of age, in all their mental and physical capacities to decide to be part of this study. 2. There are no comorbidities or associated diseases that put the stability of the patient at risk. 3. Not be diagnosed as Chronic Kidney Disease, in any stage. 4. Existence of non-obstructive stones smaller than 10 mm located in the renoureteral path. 5. No compromise of renal viability.
Exclusion criteria
1. Patients under 18 years of age. 2. Existence of comorbidities or associated diseases that put the stability of the patient at risk. 3. Existence of a diagnosis of Chronic Kidney Disease, at any stage. 4. Presence of non-obstructive or obstructive stones greater than 10 mm located in the renoureteral path. 5. Renal viability compromise.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| kidney stone clearance with Renalof® treatment compared to placebo | 4 months | kidney stone clearance with Renalof® treatment compared to placebo measured by ultrasound and tomography imaging |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life of patients | 4 months | Quality of life was established in relation to the presence or absence of symptoms related to the disease by means of a bimonthly personal questionnaire: dysuria or burning when urinating, urinary urgency, kidney colic, difficulty in performing daily activities and periodicity of urinary infections (mild, moderate, severe, yes or no,). |
| Number of colic | 4 months | number of colic during the 4-month follow-up of treatment |
| Adverse events related with product of the trial | 4 months | Adverse effects related with the test product in patients with kidney stones, measured by means of a bimonthly personal questionnaire: nausea, vomiting, digestive pain, stomach ache... (mild, moderate, severe, yes or no,). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Cost of treatment | 4 months | cost of treatment with the use of Renalof® compared to the usual treatments, taking into account hospitalization time due to the number of colic and recovery time due to urolithiasis |
Countries
Nicaragua
Outcome results
None listed